Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting.
SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call:
-- April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)." AUA Late-Breaking Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375 at McCormick Place -- April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT - Abstract #1408: "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia." Poster presentation to occur in the Benign Prostatic Hyperplasia: Basic Research session. Room W375B at McCormick Place -- April 28, 2009, 4:30 p.m. CDT - IMPACT data webcast conference call
The IMPACT (IMmunotherapy for Prostate AdenoCarcinoma adenocarcinoma: see neoplasm. Treatment) study evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational product candidate for men with advanced prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system immune system
Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. against cancer. Dendreon announced last week that the IMPACT trial met its primary endpoint of improving overall survival compared to a placebo control.
To access the live conference call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at http://www.dendreon.com/ under the "Investor/Webcasts and Presentations" section. There will be a slide presentation to accompany the call, which will also be available on this section of the Dendreon website. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 (domestic) or 719-457-0820 (international); the conference ID number is 6483399. The replay will be available from 8:00 p.m. ET, April 28, 2009 until midnight April 29, 2009. In addition, the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com/.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response immune response
An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. . Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia benign prostatic hyperplasia
n. Abbr. BPH
A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. . The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
CONTACT: Jennifer Cook Williams, Investor Relations Investor relations
The process by which the corporation communicates with its investors. of Dendreon Corporation, +1-206-829-1500; or media, Katherine Stueland of WeissComm Partners, +1-312-608-0320, email@example.com, for Dendreon Corporation
Web Site: http://www.dendreon.com/